AI‑Generated Viruses: Synthetic Biology Breakthrough Sparks Therapeutic Promise and Biosecurity Debate
US researchers have engineered 16 novel bacteriophages using generative AI, the first time whole viral genomes have been designed from scratch.
These phages are fully functional, replicate in laboratory conditions, and specifically target Escherichia coli strains without posing any risk to humans.
Designing viruses from genetic codes stored in models dubbed Evo1 and Evo2, the AI predicts entire genomes similarly to large language models that generate text.
Experts emphasize that while this technology could unlock antibiotic‑resistant treatment options and rapid pharmaceutical development, it raises urgent biosafety and biosecurity questions.
In a recent commentary, scientists warn that “new viruses that could cause disease should not be pursued,” underscoring the need for rigorous safeguards.
The team excluded pathogenic genomes from training data, focused on phages rather than human‑infecting viruses, and performed synthesis in a secure laboratory, arguing these measures maintain safety.
Some researchers, including Stanford assistant professor Brian Hie, view the work as a “turning point” that opens possibilities for engineered therapies ranging from phage treatment of bacterial infections to the creation of novel enzymes and antibodies.
However, the capacity for AI to craft biologically active, replicating genomes underscores a broader shift toward synthetic biology and the ethical dimensions of creating life‑forms in a box.
The broader biomedical community views this milestone as a foundational step toward AI‑assisted genome writing, potentially allowing the design of even simpler organisms in the future.
